CAPTRUST Financial Advisors
NGNE icon

CAPTRUST Financial Advisors’s Neurogene NGNE Stock Holding History

CAPTRUST Financial Advisors’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-46
Closed -$2K – 5066
2022
Q1 		$2K Buy
+46
New +$2.68K ﹤0.01% 4511
2020
Q4 		– Sell
-13
Closed -$3K – 3473
2020
Q3 		$3K Buy
+13
New +$3.15K ﹤0.01% 2675

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAPTRUST Financial Advisors's NGNE Position: Q2 2022 in Review

CAPTRUST Financial Advisors sold out of Neurogene (NGNE) in Q2 2022, closing a stake of 46 shares — an estimated $2K sold.

CAPTRUST Financial Advisors first reported a position in NGNE in Q3 2020 and held it in 2 quarters. The position peaked at $3K in Q3 2020. 63 funds tracked by Wall St. Rank hold NGNE as of Q2 2022.

  • CAPTRUST Financial Advisors reported no remaining Neurogene position as of Q2 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 46 Neurogene shares in Q2 2022, an estimated $2K.
  • CAPTRUST Financial Advisors first reported a position in Neurogene in Q3 2020 and held it in 2 quarters.
  • CAPTRUST Financial Advisors's Neurogene position peaked at $3K in Q3 2020.
  • 63 funds tracked by Wall St. Rank held Neurogene as of Q2 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2022, filed 16 Aug 2022.